USFDA approves Glenmark Pharmaceuticals’ bacterial infection capsules

Glenmark Pharmaceuticals Limited on Tuesday announced that it has received final approval from the United States Food & Drug Administration (U.S. FDA) for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, the generic version of Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg, of Pfizer Inc.

According to the company’s press statement, Glenmark’s Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

According to IQVIATM sales data for the 12-month period ending January 2023, the Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg market2 achieved annual sales of approximately $33.6 million.

Also Read

Enzene Biosciences launches first biosimilar of Cancer treatment drug Erbitux

This drug works better than caffeine in keeping daytime sleepiness at bay; Here are the details

Pharma retail emerges new frontier for organised players

70-80% of APIs are imported from China; We are working towards filling this gap: Dr. Sanjay Chaturvedi, CEO, IOL Chemicals and Pharmaceuticals

Glenmark’s current portfolio consists of 181 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA.